Dupilumab for recalcitrant prurigo nodularis: Case report

Joel Reis; Inês Raposo; Manuela Selores

Revista da Sociedade Portuguesa de Dermatologia e Venereologia (Jan 2022)

Dupilumab for recalcitrant prurigo nodularis: Case report

Joel Reis,
Inês Raposo,
Manuela Selores

Affiliations

Joel Reis: Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal
Inês Raposo: Department of Dermatology, University of Porto. Portugal
Manuela Selores: Department of Dermatology; Department of Dermatology and Dermatology Research Unit, Centro Hospitalar Universitário do Porto; Instituto de Ciências Biomédicas Abel Salazar; Unit for Multidisciplinary Research in Biomedicine, University of Porto. Porto, Portugal

Journal volume & issue: Vol. 80, no. 1

Abstract

Read online

Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. We present a case of recalcitrant prurigo nodularis treated off-label with dupilumab.

Antibodies. Monoclonal. Humanized. Dupilumab. Prurigo/drug therapy.

Published in Revista da Sociedade Portuguesa de Dermatologia e Venereologia

ISSN: 2182-2395 (Print); 2182-2409 (Online)
Publisher: Sociedade Portuguesa de Dermatologia e Venereologia
Country of publisher: Portugal
LCC subjects: Medicine: Dermatology; Medicine: Internal medicine: Infectious and parasitic diseases
Website: https://revista.spdv.com.pt

About the journal

Abstract

Keywords